Head to head
Arcutis Biotherapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: ARQT · VRTX
ARQT
Arcutis Biotherapeutics
26.36-2.98%
1-year price shape — -4% over the period
Quant Rating D · 33/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
| ARQT | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 26.36 | 515.02 |
| Change today | -2.98% | -1.08% |
| 1-year return | -3.5% | +22.0% |
| Market cap | $3.33B | $130.58B |
| 52-week range | 19.30 – 34.80 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | 119.82 | 33.14 |
| P/E percentile, own 5-yr range | 99th | 99th |
| P/B | 13.67 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.13 | 15.32 |
| Net profit (TTM) | $-16.44M | $3.88B |
| Revenue (TTM) | $508.68M | $12.95B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +45.1% | +11.8% |
| Gross margin | 91.2% | 85.5% |
| Operating margin | 6.9% | 33.1% |
| Net margin | 5.9% | 30.7% |
| Free cash flow (TTM) | $59.71M | $3.20B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 121.5% | 96.8% |
| Insider activity (12mo) | 20 buy / 26 sell | 28 buy / 22 sell |
| Short interest (% of float) | 14.4% | 1.9% |
| Analyst consensus | 100% buy (5) | 95% buy / 5% hold (21) |
| Analyst price target | $42 (+59%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | D (33) | C (68) |
| Company | ||
| Employees | 354 | 6,400 |
| Founded | 2016 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.